Phase 1 study and population PK/PD modeling of long-acting growth hormone, GB08, to guide pediatric dosing
Authors:
- 17 June 2025
- journal article
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 193 (1) , 117-128
Abstract
Objective: Growth hormone deficiency (GHD) requires long-term treatment, but daily injections and adverse effects of current therapies often pose adherence challenges in children. GB08, a novel Fc-GH, leverages the extended half-life of Fc-fusion proteins to reduce injection frequency with potential for improved safety. This study evaluates the safety, immunogenicity, pharmacokinetics, and pharmacodynamics profiles of GB08 in healthy adults. The findings, along with population PK/PD modeling, will guide dosing strategies for a Phase 2 trial in pediatric GHD patients. Design: The study consisted of 2 parts: a randomized, double-blind, placebo-controlled single ascending dose trial and a randomized, open-label, parallel-group positive control trial. Methods: Subjects received a single dose of GB08 (0.16-2.4 mg/kg), 0.2 mg/kg of Jintrolong, or 7 daily doses of Norditropin (0.035 mg/kg/day). Evaluations included adverse events (AEs), immunogenicity, pharmacokinetics, and pharmacodynamics. Results: GB08 demonstrated a favorable safety profile with low immunogenicity, no serious AEs reported, and all AEs were mild to moderate. Pharmacokinetics and pharmacodynamics revealed dose-dependent increases, with GB08's half-life ranging from 81.7 to 110.0 h, supporting its potential for once-weekly injection. PK/PD modeling identified an optimal adult dose of 0.7 mg/kg. Further allometric scaling of adult PK data to develop a pediatric PK model suggested optimal pediatric dose of 0.8 mg/kg, balancing efficacy and safety profiles. Conclusion: GB08 provides notable advantages over traditional therapies, like short-acting GH, by enhancing treatment adherence and offering a potentially safer alternative. The findings from this study will guide dosing strategies for Phase 2 trial in children with GHD.Keywords
Funding Information
- Shenzhen Kexing Biopharm Co., Ltd
This publication has 40 references indexed in Scilit:
- Population Pharmacokinetics and Pharmacodynamics of Once-Daily Growth Hormone Norditropin® in Children and AdultsClinical Pharmacokinetics, 2021
- Effect of growth hormone on insulin signalingMolecular and Cellular Endocrinology, 2020
- A review of growth hormone deficiencyPaediatrics and Child Health, 2019
- Pharmacokinetics and Pharmacodynamics of Once-Weekly Somapacitan in Children and Adults: Supporting Dosing Rationales with a Model-Based Analysis of Three Phase I TrialsClinical Pharmacokinetics, 2018
- Growth hormone — past, present and futureNature Reviews Endocrinology, 2018
- Effect of recombinant human growth hormone therapy on blood lipid and carotid intima-media thickness in children with growth hormone deficiencyPediatric Research, 2018
- Single chain Fc-dimer-human growth hormone fusion protein for improved drug deliveryBiomaterials, 2017
- PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved DrugsJournal of Pharmaceutical Sciences, 2016
- Pharmacokinetics, Pharmacodynamics, and Efficacy of a Novel Long-Acting Human Growth Hormone: Fc Fusion ProteinMolecular Pharmaceutics, 2015
- Treatment with growth hormone suppresses cortisol production in manMetabolism, 1998